Rapport Therapeutics (RAPP) drew fresh investor attention after reporting second quarter 2026 results and outlining progress across its central nervous system pipeline, including new Phase 3 trials for lead candidate RAP-219.

The clinical updates appear to have coincided with a sharp re-rating in investor expectations, with Rapport Therapeutics posting a 1-day share price return of 9.21% and a year to date share price return of 64.89%. The 1-year total shareholder return of 200.78% points to strong momentum building around the stock.

If you are looking beyond Rapport Therapeutics for other opportunities in this theme, now could be a useful moment to scan the market using our screener for 42 healthcare AI stocks

After such a strong run and with Rapport Therapeutics still reporting losses, the key issue now is balance. Does the current price fairly reflect both the clinical progress and the risks ahead for new buyers?

Preferred Price-to-Book Multiple of 5.3x: Is It Justified?

With Rapport Therapeutics closing at $46.35 and trading on a P/B of 5.3x, the stock is priced above the broader US Pharmaceuticals industry but slightly below its closest peer group on this metric.

The P/B ratio compares the company’s market value to its book value, which can be a useful shorthand for how much investors are willing to pay for each dollar of net assets. For a clinical-stage biopharmaceutical company like Rapport Therapeutics, where current earnings are negative and cash flows are still developing, asset based measures often attract more attention than profit based ones.

On a peer comparison, Rapport Therapeutics sits below the 5.9x average of similar companies that it is benchmarked against, which points to relatively restrained pricing versus that subset. Against the wider US Pharmaceuticals industry, where the average P/B is 2.6x, the stock trades at a clear premium. That split view suggests the market is already assigning a higher value to its CNS pipeline and revenue growth outlook than to the typical industry company, even though the business is still loss making.

Result: Price-to-book of 5.3x (ABOUT RIGHT)

However, Rapport Therapeutics still reports a loss of $137.16 million on revenue of $20 million, and any setback in RAP-219 trials could quickly challenge sentiment.

Next Steps

Given the mix of excitement and caution around Rapport Therapeutics, this is a moment to move quickly, review the full picture, and decide where you stand using its 1 key reward and 3 important warning signs.

Looking For More Investment Ideas Beyond Rapport Therapeutics?

If you want to keep building on your work with Rapport Therapeutics, do not stop here. Fresh ideas can help you stay ahead of the next move.

• Target potential mispricing opportunities by scanning 49 high quality undervalued stocks that combine quality fundamentals with more modest market expectations.
• Strengthen the income side of your portfolio by reviewing 8 dividend fortresses that focus on higher yielding companies.
• Dial back risk while staying invested by checking 78 resilient stocks with low risk scores that show more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.